Prosecution Insights
Last updated: October 24, 2026
Application No. 19/011,409

BRANCHED MULTI-FUNCTIONAL MACROMONOMERS AND RELATED POLYMERS AND USES THEREOF

Non-Final OA §DP
Filed
Jan 06, 2025
Priority
Jun 30, 2017 — provisional 62/528,010 +3 more
Examiner
DAVIS, BRIAN J
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Massachusetts Institute of Technology
OA Round
1 (Non-Final)
85%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
81%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
1350 granted / 1592 resolved
+24.8% vs TC avg
Minimal -4% lift
Without
With
+-3.9%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 9m
Avg Prosecution
47 currently pending
Career history
1640
Total Applications
across all art units

Statute-Specific Performance

§101
5.2%
-34.8% vs TC avg
§103
16.5%
-23.5% vs TC avg
§102
19.5%
-20.5% vs TC avg
§112
44.9%
+4.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1592 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The lined-through reference is incomplete (no date). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 17, 51, 125, 157 and 165 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, 6, 10, 27 and 28 of (parent) U.S. Patent No. 10,716,858 B2, cited in the IDS. Although the claims at issue are not identical, they are not patentably distinct from each other. Instant independent claim 1 is simply a subset of the macromonomer compounds of patented independent claim 1. The subject matter of instant dependent claim 51 is identical to the subject matter of patented dependent claim 2. The subject matter of instant dependent claim 157 is identical to the subject matter of patented dependent claim 6. The subject matter of instant dependent claim 165 is identical to the subject matter of patented dependent claim 10. The subject matter of instant dependent claim 125 is identical to the subject matter of patented dependent claim 27. The subject matter of instant dependent claim 17 is identical to the subject matter of patented dependent claim 28. In sum, the instantly claimed subject matter is simply a subset of the claimed subject matter of the parent patent and as such is fully encompassed by the claims of the parent. Claims 1 and 157 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 4 of (parent) U.S. Patent No. 12,186,396 B2, cited in the IDS. Although the claims at issue are not identical, they are not patentably distinct from each other. Instant independent claim 1 is simply a subset of the macromonomer compounds of patented independent claim 1. The subject matter of instant dependent claim 157 is identical to the subject matter of patented dependent claim 4. In sum, the instantly claimed subject matter is simply a subset of the claimed subject matter of the parent patent and as such is fully encompassed by the claims of the parent. Allowable Subject Matter Claims 13, 50, 126, 127, 158-164 and 166-168 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: The key to the instant invention is the Markush set of compounds of Formula (I). The closest art is inventor’s own work (the parent patents) cited above. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EDT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush, can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN J DAVIS/Primary Examiner, Art Unit 1614 9/24/2026
Read full office action

Prosecution Timeline

Jan 06, 2025
Application Filed
Sep 29, 2026
Non-Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758498
A TOPICAL GEL FORMULATION FOR SKIN AND MOUTH DISORDERS AND A PROCESS OF PREPARATION THEREOF
2y 3m to grant Granted Oct 13, 2026
Patent 12751936
BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER
7y 3m to grant Granted Oct 06, 2026
Patent 12747253
KRAS G12D INHIBITORS
3y 8m to grant Granted Sep 29, 2026
Patent 12746193
COSMETIC COMPOSITION
2y 9m to grant Granted Sep 29, 2026
Patent 12746293
DNA Vector Delivery Using Lipid Nanoparticles
2y 10m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
85%
Grant Probability
81%
With Interview (-3.9%)
1y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1592 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month